United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 5 mg - dronabinol capsules are indicated for the treatment of: - anorexia associated with weight loss in patients with aids; and - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in any patient who has a known sensitivity to dronabinol capsules or any of their ingredients. dronabinol capsules contain cannabinoid and sesame oil and should never be used by patients allergic to these substances. dronabinol is one of the psychoactive compounds present in cannabis, and is abusable and controlled [schedule iii (ciii)] under the controlled substances act. both psychological and physiological dependence have been noted in healthy individuals receiving dronabinol, but addiction is uncommon and has only been seen after prolonged high dose administration. chronic abuse of cannabis has been associated with decrements in motivation, cognition, judgement, and perception. the etiology of thes

United States - English - NLM (National Library of Medicine)

american health packaging - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg - dronabinol capsules are indicated for the treatment of: - anorexia associated with weight loss in patients with aids; and - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments dronabinol capsules are contraindicated in any patient who has a known sensitivity to dronabinol or any of its ingredients. it contains cannabinoid and sesame oil and should never be used by patients allergic to these substances. dronabinol is one of the psychoactive compounds present in cannabis, and is abusable and controlled [schedule iii (ciii)] under the controlled substances act. both psychological and physiological dependence have been noted in healthy individuals receiving dronabinol, but addiction is uncommon and has only been seen after prolonged high dose administration. chronic abuse of cannabis has been associated with decrements in motivation, cognition, judgment, and perception. the etiology of these impairments is unknown, but may

United States - English - NLM (National Library of Medicine)

akorn - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have b

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have been found in

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg - dronabinol capsules are indicated for the treatment of: - anorexia associated with weight loss in patients with aids; and - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in any patient who has a known sensitivity to dronabinol or any of its ingredients. it contains cannabinoid and sesame oil and should never be used by patients allergic to these substances. dronabinol is one of the psychoactive compounds present in cannabis, and is abusable and controlled [schedule iii (ciii)] under the controlled substances act. both psychological and physiological dependence have been noted in healthy individuals receiving dronabinol, but addiction is uncommon and has only been seen after prolonged high dose administration. chronic abuse of cannabis has been associated with decrements in motivation, cognition, judgment, and perception. the etiology of these impairments is unknown, but ma

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 5 mg - dronabinol capsules are indicated for the treatment of: - anorexia associated with weight loss in patients with aids; and - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in any patient who has a known sensitivity to dronabinol or any of its ingredients. it contains cannabinoid and sesame oil and should never be used by patients allergic to these substances. dronabinol is one of the psychoactive compounds present in cannabis, and is abusable and controlled [schedule iii (ciii)] under the controlled substances act. both psychological and physiological dependence have been noted in healthy individuals receiving dronabinol, but addiction is uncommon and has only been seen after prolonged high dose administration. chronic abuse of cannabis has been associated with decrements in motivation, cognition, judgment, and perception. the etiology of these impairments is unknown, but ma

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg - dronabinol capsules are indicated for the treatment of: dronabinol capsules are contraindicated in any patient who has a known sensitivity to dronabinol or any of its ingredients. it contains cannabinoid and sesame oil and should never be used by patients allergic to these substances. dronabinol is one of the psychoactive compounds present in cannabis, and is abusable and controlled [schedule iii (ciii)] under the controlled substances act. both psychological and physiological dependence have been noted in healthy individuals receiving dronabinol, but addiction is uncommon and has only been seen after prolonged high dose administration. chronic abuse of cannabis has been associated with decrements in motivation, cognition, judgment, and perception. the etiology of these impairments is unknown, but may be associated with the complex process of addiction rather than an isolated effect of the drug. no such decrements in psychological, social or neurological status have been associated with the administration of

United States - English - NLM (National Library of Medicine)

lannett company, inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) -    dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions ( 6.2 )] . risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations ] . cannabinoids

United States - English - NLM (National Library of Medicine)

rhodes pharmaceuticals l.p. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules, usp are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, and throat tightness [see adverse reactions (6.2)] . risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids

United States - English - NLM (National Library of Medicine)

american health packaging - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules, usp are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations